R&D

Neural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals

Neural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals

Written by on October 20, 2014 in Regenerative Medicine, Research & Development with 0 Comments

Richard Garr, President and Chief Executive Officer, Neuralstem joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘Neural Stem Cell Technology Platform Cell Therapy and Pharmaceuticals.’ Download this presentation now to find out: Technology –Cells Nurturing, Supporting and Rescuing Remaining Neurons Platform- Cell Therapeutics’ Commercialization and Platform Roll-out Small […]

Continue Reading

The new Apollo™ mammalian expression system

The new Apollo™ mammalian expression system

There is undoubtedly a great deal of research going on within the antibody space, a significant number of therapeutics in the clinic and a lot of upcoming developments to watch out for. In preparation for the European Antibody Congress 2014, we took some time out to interview FUJIFILM Diosynth Biotechnologies’, Bo Kara, Director Science and Technology, about […]

Continue Reading

Drug Discovery

Could Antibodies Provide the Answer to Curing Ebola?

Could Antibodies Provide the Answer to Curing Ebola?

Written by on October 17, 2014 in Drug Discovery with 0 Comments

Newly discovered antibody drugs such as ZMAPP could provide a solution to the Ebola epidemic that’s sweeping across the globe. We have known about the capacity of antibodies for modulating the immune system for decades, and there are already hundreds of antibody-based drugs that are used to effectively fight various illnesses such as cancer and […]

Continue Reading

Regenerative Medicine: the cure for heart failure?

Regenerative Medicine: the cure for heart failure?

Written by on October 13, 2014 in Drug Discovery with 0 Comments

Rahul Aras, Chief Executive Officer, Juventas Therapeutics and Marc S. Penn, MD, PhD, Founder and CMO, Juventas Therapeutics joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on the potential application of regenerative medicine to cure heart failure. Download this presentation now to find out: The Juventas Hypothesis SDF-1: A Natural […]

Continue Reading

Clinical Trials

Birmex Discute el Mercado de Vacunas en México

Birmex Discute el Mercado de Vacunas en México

Written by on October 14, 2014 in Clinical Trials, Manufacturing, Reports with 0 Comments

Samuel Ponce de León es el director general de Laboratorios Biológicos y Reactivos de México (BIRMEX). Estudió medicina en la Universidad Nacional Autónoma de México (UNAM) con especialidad en medicina interna y enfermedades infecciosas en el Instituto Nacional de Nutrición. Realizó los estudios de maestría en epidemiología hospitalaria en la universidad de Virginia, Charlotresville en […]

Continue Reading

Early Clinical Trials: What is different?

Early Clinical Trials: What is different?

Written by on October 6, 2014 in Clinical Trials, Regenerative Medicine with 0 Comments

Paul Williamson, Janssen Research and Development, joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘Early Clinical Trials: What is different?’ Download this presentation now to find out: New Work Streams New Challenges Refinement of a Surgical Delivery System Regulation restrictions …and much more! Get your copy here! […]

Continue Reading

Manufacturing

What is the key to safe highly potent active pharmaceutical ingredient (HPAPI) manufacturing?

What is the key to safe highly potent active pharmaceutical ingredient (HPAPI) manufacturing?

Written by on October 17, 2014 in Featured on app, Manufacturing with 0 Comments

Innovating highly potent active pharmaceutical ingredient (HPAPI) production philosophies can ensure safety for those involved in their manufacturing, but what are the best pathways to innovate whilst reducing risks?   The fast growing HPAPI sector fosters huge potential, and with an annual growth rate exceeding double figures, it has become something of a ‘promised land’ […]

Continue Reading

Increase in Continuous Processing and Single-Use in Future Biomanufacture Forecast in New Review

Increase in Continuous Processing and Single-Use in Future Biomanufacture Forecast in New Review

Written by on October 3, 2014 in Manufacturing with 0 Comments

A review by Institute for Separation and Process Technology has predicted an increase in the use of single use technologies and continuous processing within the manufacture of biologics in the future. Researchers Jochen Strube, Reinhard Ditz and Petra Gronemeyer, predict that demands for high quality biologics will continue to increase in the coming decades. Decreasing production and imminent patent […]

Continue Reading

Regulation & Compliance

UK Stem Cell Initiative approaches 10th anniversary

UK Stem Cell Initiative approaches 10th anniversary

Written by on September 29, 2014 in Featured on app, Regulation and Compliance with 0 Comments

The UK Stem Cell Initiative report was warmly received by the Government in 2005 and provided them with a “clear vision for future endeavour with indicative costs for a strategy to maintain the UK’s position as a world leader in basic research” – nearly 10 years on, how have the recommendations developed? In the Budget […]

Continue Reading

COFEPRIS Presents the Case of Mexico

COFEPRIS Presents the Case of Mexico

Written by on September 4, 2014 in Featured on app, Regulation and Compliance, Reports with 0 Comments

Mikel Arriola was born in Mexico City and was appointed Federal Commissioner for Protection from Sanitary Risks on March, 2011. He studied Law at the Universidad Anáhuac as a Bachelor Degree, has a Master Degree on Public Policy and Public Administration by the London School of Economics and Political Science of London, United Kingdom and […]

Continue Reading

Pricing & Market Access

How can patient reported outcomes generate evidence to validate health claims?

How can patient reported outcomes generate evidence to validate health claims?

Written by on October 22, 2014 in Pricing & Market Access, Reports with 0 Comments

At Evidence EU 2014, Tara Symonds , Senior Director, Pfizer, gave a presentation on  “How can patient reported outcomes generate evidence to validate health claims?” Symonds’ presentation reveals her belief that PRO data is increasingly seen as important by payers for validating health claims from a patient perspective. She also mentions both the EU HTA community and […]

Continue Reading

Value based assessment: NICE’s role

Value based assessment: NICE’s role

Written by on October 15, 2014 in Pricing & Market Access, Reports with 0 Comments

At Pharma Pricing & Market Access Europe 2014, David Haslam, Chairman, NICE, gave a presentation on “Value based assessment: NICE’s role” Haslam’s presentation discussed  incorporating burden of illness and wider societal impact into NICE’s technology assessment methods. Download and learn: Value Based Assessment NICE’s current approach Costs and benefits New DH terms of reference Approaches to […]

Continue Reading

Engagement & Marketing

3 ways to use social media as a healthcare professional

3 ways to use social media as a healthcare professional

Written by on October 24, 2014 in Engagement & Communications, Featured on app with 0 Comments

Whether you are a healthcare clinician or patient, biotech CEO or an academic professor, there is a social media platform for you. Those who know me will know that I am a big advocate of using different social media platforms to engage with your communities. That said, what can be deemed as productive can often […]

Continue Reading

At what stage do advances in stem cell therapies risk crossing the bio-ethics line?

At what stage do advances in stem cell therapies risk crossing the bio-ethics line?

Written by on October 10, 2014 in Engagement & Communications, Featured on app with 0 Comments

The past 12 months have seen successes in stem cell therapies but as the medical practices advance, fears are rising that, with regards to bio-ethics, they are going too far. This week the international stem cell industry has been busy celebrating the 8th annual ‘Stem Cell Awareness Day’. It has been a great opportunity to […]

Continue Reading

Partnering & Investment

Promising scale and market success for cell therapies after large financial injection

Promising scale and market success for cell therapies after large financial injection

Written by on September 19, 2014 in Featured on app, Partnering & Investment with 0 Comments

In a report released this week, by BCC Research, it was forecasted that the global market for stem cells (including cell therapies) is to reach US $10.6 billion in 2018. However with currently no medicines, based on stem cells, having yet received marketing authorisation from the EMA*, or the FDA*, how are we going to get there? […]

Continue Reading

An investor perspective and analysis of the stem cell & regenerative medicine sector

An investor perspective and analysis of the stem cell & regenerative medicine sector

Written by on September 12, 2014 in Partnering & Investment, Regenerative Medicine with 0 Comments

Dr. Navid Malik B.Sc. M.Sc. MBA, Cenkos joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present on ‘An investor perspective and analysis of the stem cell & regenerative medicine sector’ Download this presentation now to find out: Cenkos Securities’ focus on Life Sciences Longer-term sector returns have been very […]

Continue Reading

Other Recent Posts

Banco de Cordón Umbilical en la Extracción de Células Madre Mesenquimales

Diana Pier Gary es la directora médica de Banco del Cordón Umbilical, S.A. Cursó los estudios de licenciatura en nutrición y ciencia de los alimentos con especialización en nutrición humana en la Universidad Iberoamericana. Obtuvo diplomados en genética molecular e histocompatibilidad por el Departamento de Inmunogenética de la Secretaria de Salud. En 2013, Diana dio […]

Continue Reading

Small is beautiful: Winning in the highly competitive generics market

At the World Generic Medicines Congress Europe 2014, John Beighton, CEO,  Amdipharm Mercury Company Ltd gave a presentation on “Small is beautiful: Winning in the highly competitive generics market” Beighton’s presentation explores an entrepreneur’s dilemma of “How to grow without losing the “spirit” of what creates value” Download and learn: Strategic Growth Background: The In-market value chain Global Coverage […]

Continue Reading

Guest Post:  GaBI – Building trust in cost-effective treatments

A frequent partner of our Life Science conferences, GaBI Journal is an independent and peer reviewed academic journal, encompassing all aspects of generic and biosimilar medicines development and use, from fundamental research up to clinical application and policies. View the latest issue of GaBI Journal to learn about pharmaceutical innovation and developments in generic and biosimilar […]

Continue Reading

DARA BioSciences Product Gelclair® Attains Market Leadership Position in U.S. Retail Market

October 14, 2014: DARA BioSciences, Inc., an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced today that its product, Gelclair®, indicated for the management of  oral mucositis, has attained a […]

Continue Reading

Relocation and Upgrade solution for Actavis Malta

Pharmaceutical company Actavis commissioned Extract Technology Ltd to carry out a relocation project as part of its state-of-the-art warehouse at the Bulebel Industrial Estate, Malta. The investment into bigger warehousing facilities was due to a significant increase in the Bulebel site manufacturing output, where volume has practically tripled over the last 7 years. It was […]

Continue Reading

Top
Geolocation